-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $50

Benzinga·10/21/2026 15:01:17
TD Cowen analyst Stacy Ku maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $60 to $50.